OYSTER POINT PHARMACEUTICALS
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).
OYSTER POINT PHARMACEUTICALS
Industry:
Biopharma Clinical Trials Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.oysterpointrx.com
Total Employee:
11+
Status:
Active
Total Funding:
235.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Wordpress Plugins
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
2017-10-01
Current Employees Featured
Donald J. Santel Non-executive Chairperson, Director @ Oyster Point Pharmaceuticals
Non-executive Chairperson, Director
2021-07-01
Michael Ackermann Chairman @ Oyster Point Pharmaceuticals
Chairman
2017-10-01
Loni da Silva Senior Vice President, Regulatory Affairs @ Oyster Point Pharmaceuticals
Senior Vice President, Regulatory Affairs
Mark Murray CFO @ Oyster Point Pharmaceuticals
CFO
Jeffrey Nau CEO @ Oyster Point Pharmaceuticals
CEO
2017-03-01
Patricia Johnson Executive Director, Regulatory CMC @ Oyster Point Pharmaceuticals
Executive Director, Regulatory CMC
2018-04-01
JOHN SNISARENKO Chief Commercial Officer @ Oyster Point Pharmaceuticals
Chief Commercial Officer
Puja Shah Medical Director @ Oyster Point Pharmaceuticals
Medical Director
2020-12-01
DANIEL LOCHNER Chief Financial Officer @ Oyster Point Pharmaceuticals
Chief Financial Officer
Founder
Stock Details
Investors List
Flying L Partners
Flying L Partners investment in Series B - Oyster Point Pharmaceuticals
Vida Ventures
Vida Ventures investment in Series B - Oyster Point Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series B - Oyster Point Pharmaceuticals
Invus
Invus investment in Series B - Oyster Point Pharmaceuticals
Versant Ventures
Versant Ventures investment in Series B - Oyster Point Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series A - Oyster Point Pharmaceuticals
Versant Ventures
Versant Ventures investment in Series A - Oyster Point Pharmaceuticals
Official Site Inspections
http://www.oysterpointrx.com Semrush global rank: 3.82 M Semrush visits lastest month: 3.47 K
- Host name: edge.redirect.pizza
- IP address: 89.106.200.1
- Location: Luxembourg
- Latitude: 49.7498
- Longitude: 6.1661
- Timezone: Europe/Luxembourg
More informations about "Oyster Point Pharmaceuticals"
Oyster Point Pharmaceuticals - Crunchbase Company …
Contact Email info@oysterpointrx.com Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and …See details»
Oyster Point Pharma - Wikipedia
The company was founded in 2015. In October 2021, Tyrvaya was the first nasal spray approved by Food and Drug Administration to treat dry eye syndrome. This became the company's lead product. Prior to going public, Oyster Point Pharma operated at a loss of $16.5 million in 2018. In February 2019, still at clinical stage, the company raised $93 million in its Series B funding rou…See details»
Oyster Point Pharma - LinkedIn
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.See details»
Oyster Point Pharma - Overview, News & Similar companies
David Benadon has joined the organization as Chief Human Resources Officer. Executive Moves, New Hire. Nov 30 2021 ... 382-9032 Website: www.oysterpointrx.com What does Oyster Point …See details»
Oyster Point Pharma Company Profile | Management and
Www.oysterpointrx.com Oyster Point Pharma Profile and History Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and …See details»
Oyster Point Pharmaceuticals - 2025 Company Profile - Tracxn
Mar 7, 2025 Email ID: *****@oysterpointrx.com; Key Metrics. Total Funding. $122M in 2 rounds. Latest Funding Round. Series B, Feb 26, 2019, $93M. Investors. New Enterprise Associates & …See details»
Oyster Point Pharma Information - RocketReach
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to …See details»
Oyster Point Pharma Overview | SignalHire Company Profile
Organization Website: oysterpointrx.com : Social Links: Phone Number: 609-382-9032: Oyster Point Pharma industries Pharma, Pharmaceuticals: Headquarters Location: 202 CARNEGIE …See details»
Oyster Point Pharma - businessabc.net
Feb 25, 2025 Oyster Point was founded in 2014 by two industry veterans with decades of experience in the biopharmaceutical space. Oyster Point has since grown to become a leader …See details»
Oyster Point Pharma - Craft
Jan 11, 2023 Oyster Point Pharma has 2 employees at their 1 location and $24.54 m in annual revenue in FY 2021. See insights on Oyster Point Pharma including office locations, …See details»
Oyster Point 2025 Company Profile: Valuation, …
Www.oysterpointrx.com. Ownership Status. Acquired/Merged (Operating Subsidiary) Financing Status. Corporate Backed or Acquired. Corporate Office. 202 Carnegie Center; Suite 106; Princeton, NJ 08540; United StatesSee details»
Organization: Oyster Point Pharma - Cbonds.com
Organization name. Oyster Point Pharma, Inc. Country name. USA Country of registration. USA. Industry. Pharmaceutical Preparation and Biotechnology. Bond debt - ...See details»
Oyster Point Pharma: Employee Directory | ZoomInfo.com
Oyster Point Pharma Contact Info: Phone number: (609) 382-9032 Website: www.oysterpointrx.com What does Oyster Point Pharma do? Oyster Point Pharma is a clinical …See details»
Oyster Point Pharma, Inc. - Cruelty Free Investing
Company Website: https://oysterpointrx.com Contact: info@oysterpointrx.com ©2024 CrueltyFreeInvesting.org | Cruelty Free Investing is a registered 501c3 Non-Profit Organization …See details»
Oyster Point Pharmaceuticals (OYST) | Portfolio - Versant Ventures
Oyster Point is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat ocular surface disease.See details»
Working at Oyster Point Pharma - Zippia
Oysterpointrx.com. Organization Type. Public. CEO. Jeffrey A. Nau. Social Media. Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development …See details»
Oyster Point Pharma, a Leading Ophthalmology-Focused
Nov 7, 2022 Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per...See details»
Oyster Point Pharma Announces TYRVAYA® To Be Covered By the
PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a...See details»
Oyster Point Pharma Announces TYRVAYA® To Be Covered By the …
PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical …See details»
Oyster Point Pharma Announces Expansion of Executive …
PRINCETON, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, …See details»